Mitsui T, Sekido N, Masumori N et al (2024) Prevalence and impact on daily life of lower urinary tract symptoms in Japan: results of the 2023 Japan Community Health Survey (JaCS 2023). Int J Urol 31:747–754. https://doi.org/10.1111/iju.15454

Article  PubMed  PubMed Central  Google Scholar 

Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314. https://doi.org/10.1016/j.eururo.2006.09.019

Article  PubMed  Google Scholar 

Chancellor MB, Migliaccio-Walle K, Globe D et al (2013) Long-term patterns of use and treatment failure with anticholinergics for overactive bladder. Clin Ther 35:1744–1751. https://doi.org/10.1016/j.clinthera.2013.09.014

Article  CAS  PubMed  Google Scholar 

Edmondson SD, Zhu C, Kar NF et al (2016) Discovery of vibegron. J Med Chem 59:609–623. https://doi.org/10.1021/acs.jmedchem.5b01210

Article  CAS  PubMed  Google Scholar 

Yamaguchi O, Marui E, Kakizaki H et al (2014) Phase III study of mirabegron in Japanese patients with overactive bladder. BJU Int 113:951–960. https://doi.org/10.1111/bju.12566

Article  CAS  PubMed  Google Scholar 

Maman K, Aballea S, Nazir J et al (2014) Comparative efficacy and safety of medical treatments for overactive bladder. Eur Urol 65:755–765. https://doi.org/10.1016/j.eururo.2013.11.010

Article  CAS  PubMed  Google Scholar 

Fox C, Richardson K, Maidment ID et al (2011) Anticholinergic medication use and cognitive impairment in the older population. J Am Geriatr Soc 59:1477–1483. https://doi.org/10.1111/j.1532-5415.2011.03491.x

Article  PubMed  Google Scholar 

Boustani M, Campbell N, Munger S, Maidment I, Fox C (2008) Impact of anticholinergics on the aging brain. Aging Health 4:311–320. https://doi.org/10.2217/1745509X.4.3.311

Article  CAS  Google Scholar 

Lightner DJ, Gomelsky A, Souter L, Vasavada SP (2019) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults. J Urol 202:558–563. https://doi.org/10.1097/JU.0000000000000309

Article  PubMed  Google Scholar 

Dengler KL, High RA, Moga DC et al (2023) Overactive bladder and cognitive impairment. Urogynecol (Phila) 29(Suppl 1):S1–S19. https://doi.org/10.1097/SPV.0000000000001272

Article  Google Scholar 

Iyen B, Coupland C, Bell BG et al (2024) Risk of dementia associated with anticholinergic drugs for overactive bladder. BMJ Med 3:e000799. https://doi.org/10.1136/bmjmed-2023-000799

Article  PubMed  PubMed Central  Google Scholar 

Yoshida M, Takeda M, Gotoh M et al (2018) Vibegron for overactive bladder. Eur Urol 73:783–790. https://doi.org/10.1016/j.eururo.2018.01.035

Article  CAS  PubMed  Google Scholar 

Staskin D, Frankel J, Varano S et al (2020) EMPOWUR: phase III trial of vibegron in OAB. J Urol 204:316–324. https://doi.org/10.1097/JU.0000000000000805

Article  PubMed  Google Scholar 

Yoshida M, Takeda M, Gotoh M et al (2020) Efficacy of vibegron on severe urgency urinary incontinence. BJU Int 125:709–717. https://doi.org/10.1111/bju.15003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chapple CR, Nazir J, Hakimi Z et al (2017) Persistence and adherence with mirabegron versus antimuscarinics. Eur Urol 72:389–399. https://doi.org/10.1016/j.eururo.2017.01.037

Article  CAS  PubMed  Google Scholar 

Weber MA, Haag-Molkenteller C, King J et al (2022) Effects of vibegron on ambulatory blood pressure. Blood Press Monit 27:128–134. https://doi.org/10.1097/MBP.0000000000000576

Article  PubMed  PubMed Central  Google Scholar 

Nakagomi H, Mitsui T, Shimura H et al (2022) Mirabegron for overactive bladder in frail patients aged ≥ 80 years (HOKUTO study). BMC Urol 22:40. https://doi.org/10.1186/s12894-022-00989-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ozaki Y, Hatakeyama S, Imai A et al (2016) Relationship between lower urinary tract symptoms and frailty. Investig Clin Urol 57:84–93. https://doi.org/10.4111/icu.2016.57.2.84

Article  Google Scholar 

Yoshida M, Takeda M, Gotoh M et al (2021) Cardiovascular safety of vibegron in older patients. Neurourol Urodyn 40:1651–1660. https://doi.org/10.1002/nau.24727

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dmochowski RR, Rovner ES, Kennelly MJ et al (2023) COMPOSUR study design. BMC Urol 23:64. https://doi.org/10.1186/s12894-023-01227-6

Article  PubMed  PubMed Central  Google Scholar 

Gandi C, Sacco E (2021) Pharmacological management of urinary incontinence. Clin Pharmacol 13:209–223. https://doi.org/10.2147/CPAA.S291906

Article  PubMed  PubMed Central  Google Scholar 

Kim TH, Lee KS (2023) Persistence and compliance with medication in overactive bladder. Int J Urol 30:606–613. https://doi.org/10.1111/iju.15132

Article  Google Scholar 

Strong A, Steele E (2025) Optimization of overactive bladder medications in older adults. Sr Care Pharm 40:177–184. https://doi.org/10.4140/TCP.n.2025.177

Article  PubMed  Google Scholar 

Broder JC, Ryan J, Shah RC et al (2022) Anticholinergic medication burden and cognitive function. Pharmacotherapy 42:134–144. https://doi.org/10.1002/phar.2667

Article  CAS  PubMed  Google Scholar 

Ah YM, Suh Y, Jun K et al (2019) Anticholinergic burden and outcomes in dementia. Basic Clin Pharmacol Toxicol 124:741–748. https://doi.org/10.1111/bcpt.13163

Article  CAS  PubMed  Google Scholar 

Dantas LP, Forte ARCC, Lima BC et al (2022) Solifenacin and risk of dementia or cognitive impairment. Braz J Med Biol Res 55:e11721. https://doi.org/10.1590/1414-431X2022e11721

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wada N, Mizunaga M, Abe N et al (2024) Comparison of mirabegron and vibegron in female patients with OAB. World J Urol 42:113. https://doi.org/10.1007/s00345-023-04477-5

Article  CAS  PubMed  Google Scholar 

Kinjo M, Masuda K, Nakamura Y et al (2023) Mirabegron versus vibegron in treatment-naïve women with OAB. Urology 175:67–73. https://doi.org/10.1016/j.urology.2023.02.027

Article  PubMed  Google Scholar 

Mukai S, Nomi M, Yanagiuchi A, Sengoku A (2025) Comparison of the 3-year continuation rate and discontinuation factors between vibegron and mirabegron. Low Urin Tract Symptoms 17:e70001. https://doi.org/10.1111/luts.70001

Article  PubMed  Google Scholar 

Luchristt D, Bretschneider CE, Kenton K et al (2023) Inequities in filled overactive bladder medication prescriptions in the United States. JAMA Netw Open 6:e2315074. https://doi.org/10.1001/jamanetworkopen.2023.15074

Article  PubMed  PubMed Central  Google Scholar